2003
Tiagabine increases cocaine‐free urines in cocaine‐dependent methadone‐treated patients: results of a randomized pilot study
Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, George TP, Kosten TR. Tiagabine increases cocaine‐free urines in cocaine‐dependent methadone‐treated patients: results of a randomized pilot study. Addiction 2003, 98: 1625-1632. PMID: 14616189, DOI: 10.1046/j.1360-0443.2003.00544.x.Peer-Reviewed Original ResearchConceptsMethadone-treated patientsCocaine-free urinesUrine drug testsDouble-blind placebo-controlled trialCocaine useVeterans Affairs Connecticut Healthcare SystemPlacebo-controlled trialDrug testsRandomized pilot studyOpiate Withdrawal ScaleStructured Clinical InterviewSelf-reported cocaine useTreatment Research ProgramAddiction Severity IndexGABAergic medicationsActive medicationStudy entrySelf-reported useWithdrawal ScaleTreatment groupsTiagabineTreatment retentionAverage ageClinical InterviewWeek 9Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients
Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, Stine S, Gonzalez G, Gonsai K. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug And Alcohol Dependence 2003, 70: 315-325. PMID: 12757969, DOI: 10.1016/s0376-8716(03)00032-2.Peer-Reviewed Original ResearchConceptsCocaine-free urinesContingency managementCocaine useOpioid withdrawal symptomsUrine toxicology resultsDrug-free urineMethadone treatmentPoor prognosisWithdrawal symptomsMethadone maintenancePlasma levelsDependent patientsToxicology resultsTreatment groupsCell trialsCocaine abuseBuprenorphineDesipraminePatientsCocaine abusersOpiatesSymptom levelsUrineAdditive effectCocaine
2002
Ketoconazole increases cocaine and opioid use in methadone maintained patients
Kosten T, Oliveto A, Sevarino K, Gonsai K, Feingold A. Ketoconazole increases cocaine and opioid use in methadone maintained patients. Drug And Alcohol Dependence 2002, 66: 173-180. PMID: 11906804, DOI: 10.1016/s0376-8716(01)00198-3.Peer-Reviewed Original ResearchConceptsCortisol synthesis inhibitorOpioid usePlacebo treatmentCocaine useDouble-blind trialMorning cortisol levelsStress-induced reinstatementCocaine-related behaviorsSynthesis inhibitorSubstance abuse problemsMethadone treatmentWithdrawal symptomsKetoconazole treatmentPharmacological adrenalectomyClinical trialsBlind trialSide effectsCocaine abuseCortisol levelsMethadoneNormal valuesPatientsSubjective effectsKetoconazoleTreatment implicationsButorphanol and nalbuphine in opioid-dependent humans under a naloxone discrimination procedure
Oliveto A, Sevarino K, McCance-Katz E, Feingold A. Butorphanol and nalbuphine in opioid-dependent humans under a naloxone discrimination procedure. Pharmacology Biochemistry And Behavior 2002, 71: 85-96. PMID: 11812511, DOI: 10.1016/s0091-3057(01)00637-2.Peer-Reviewed Original ResearchConceptsNaloxone-appropriate respondingOpioid antagonist naloxoneDose-related increaseAntagonist naloxoneNovel-response drug discrimination procedureOpioid agonist/antagonistOpioid-dependent humansDoses of naloxoneDiscriminative stimulus effectsDrug discrimination procedureAgonists/antagonistsAppropriate respondingLow doseHigh doseNaloxoneSelf-reported effectsDiscrimination procedureDrug conditionsHigh dosesNalbuphineButorphanolDosesDoseRespondingPlacebo